Castle Biosciences(CSTL) Presents New Data Demonstrating DecisionDx-SCC Complements Current Risk Assessment Methods in Patients with SCC of the Head and Neck
Tweet Send to a Friend
Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
